Table 2. Characteristics of the patients treated with SC-treprostinil.

Patient	Sex	Cause of PAH	Age at diagnosis of PAH	Age at initiation of first treatment	Age at initiation of dual therapy	Age at initiation of SC treprostinil over both oral therapy	Oxygen saturation	NYHA functionnal class
1	M	Postoperative, TGA	3 months	7 months, bosentan	19 months, sildenafil	4 years	95%	III
2	M	Postoperative PDA	3.5 years	3.5 years, sildenafil	4 years, bosentan	5.5 years	86%	III
3	F	Small defect, VSD	2 months	9 months, sildenafil	10 months, bosentan	2.5 years	98%	III
4†	F	Small defect, ASD	6 years	7 years, bosentan	7 years, sildenafil	10 years	71%	IV
5	M	iPAH (Heritable)	4 months	5 months, sildenafil	6 months, bosentan	15 months	95%	III
6†	M	iPAH	3 months	4.5 years, bosentan	6.5 years sildenafil	10 years	89%	IV
7	F	iPAH	2 years	2 years, IV epoprostenol	5 years bosentan 7 years, sildenafil	9 years	98%	II
8	M	iPAH	16 months	16 months, bosentan	22 month, sildenafil	2.5 years	88%	IV
9	F	iPAH	12 years	12 years, directly tritherapy	/	12 years	94%	IV
10	F	iPAH	4 years	4 years	4 years sildenafil and bosentan	5 years	98%	IV

TGA, transposition of the great arteries; PDA, patent ductus arteriosus; VSD, ventricular septal defect; ASD, atrial septal defect.

^†Deceased.